3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lymphoma
224
Lymphoma, Large B-Cell, Diffuse
160
Small Cell Lung Carcinoma
154
Precursor Cell Lymphoblastic Leukemia-Lymphoma
143
Lymphoma, Non-Hodgkin
139
Leukemia
135
Leukemia, Myeloid, Acute
117
Hodgkin Disease
106
Lung Neoplasms
99
Burkitt Lymphoma
99
Lymphoma, Follicular
85
Lymphoma, Mantle-Cell
76
Lymphoma, Large-Cell, Immunoblastic
68
Carcinoma, Non-Small-Cell Lung
61
Neuroblastoma
60
Leukemia, Lymphocytic, Chronic, B-Cell
56
Recurrence
53
Multiple Myeloma
52
Lymphoma, B-Cell, Marginal Zone
43
Congenital Abnormalities
43
Sarcoma
39
Central Nervous System Neoplasms
39
Myelodysplastic Syndromes
35
Brain Neoplasms
34
Ovarian Neoplasms
32
Leukemia, Myelomonocytic, Acute
32
Lymphoma, B-Cell
31
Leukemia, Monocytic, Acute
31
Leukemia, Erythroblastic, Acute
31
Testicular Neoplasms
30
Interventions
Cisplatin
8
Carboplatin
8
Bevacizumab
8
Pleurodesis
7
Talc
6
Paclitaxel
6
Docetaxel
5
Povidone-Iodine
4
Doxycycline
4
Taxes
3
Gemcitabine
3
Drug Therapy
3
Chest Tubes
3
aldesleukin
2
Zoledronic Acid
2
Trastuzumab
2
Thoracoscopy
2
Sodium Chloride
2
Silver Nitrate
2
Pharmaceutical Preparations
2
Nivolumab
2
Interleukin-2
2
Fluorodeoxyglucose F18
2
Fentanyl
2
Erlotinib Hydrochloride
2
Cetuximab
2
Bortezomib
2
viscum album peptide
1
tocilizumab
1
tipifarnib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pleural Effusion, Malignant
×
Etoposide
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts